ARMATA PHARMACEUTICALS INC (ARMP) Stock Price & Overview

NYSEARCA:ARMP • US04216R1023

Current stock price

12.88 USD
+1.19 (+10.18%)
At close:
12.88 USD
0 (0%)
After Hours:

The current stock price of ARMP is 12.88 USD. Today ARMP is up by 10.18%. In the past month the price increased by 32.92%. In the past year, price increased by 947.15%.

ARMP Key Statistics

52-Week Range1.17 - 16.34
Current ARMP stock price positioned within its 52-week range.
1-Month Range7.4301 - 13.22
Current ARMP stock price positioned within its 1-month range.
Market Cap
471.794M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-4.66
Dividend Yield
N/A

ARMP Stock Performance

Today
+10.18%
1 Week
+7.78%
1 Month
+32.92%
3 Months
+101.25%
Longer-term
6 Months +278.82%
1 Year +947.15%
2 Years +405.10%
3 Years +695.06%
5 Years +214.15%
10 Years N/A

ARMP Stock Chart

ARMATA PHARMACEUTICALS INC / ARMP Daily stock chart

ARMP Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to ARMP. When comparing the yearly performance of all stocks, ARMP is one of the better performing stocks in the market, outperforming 99.61% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ARMP Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ARMP. Both the profitability and financial health of ARMP have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ARMP Earnings

On March 25, 2026 ARMP reported an EPS of -3.27 and a revenue of 1.08M. The company missed EPS expectations (-1044.96% surprise) and beat revenue expectations (43.75% surprise).

Next Earnings DateMay 7, 2026
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported-$3.27
Revenue Reported1.085M
EPS Surprise -1,044.96%
Revenue Surprise 43.75%

ARMP Forecast & Estimates

8 analysts have analysed ARMP and the average price target is 15.3 USD. This implies a price increase of 18.79% is expected in the next year compared to the current price of 12.88.

For the next year, analysts expect an EPS growth of 76.14% and a revenue growth -100% for ARMP


Analysts
Analysts82.5
Price Target15.3 (18.79%)
EPS Next Y76.14%
Revenue Next Year-100%

ARMP Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

ARMP Financial Highlights

Over the last trailing twelve months ARMP reported a non-GAAP Earnings per Share(EPS) of -4.66. The EPS decreased by -796.15% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-46.90M
Industry RankSector Rank
PM (TTM) N/A
ROA -52.39%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-4771.43%
Sales Q2Q%-12.15%
EPS 1Y (TTM)-796.15%
Revenue 1Y (TTM)N/A

ARMP Ownership

Ownership
Inst Owners3.39%
Shares36.63M
Float11.48M
Ins Owners0.05%
Short Float %2.59%
Short Ratio6.51

About ARMP

Company Profile

ARMP logo image Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 60 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Company Info

IPO: 1994-05-20

ARMATA PHARMACEUTICALS INC

5005 Mcconnell Ave

Los Angeles CALIFORNIA 90292 US

CEO: Todd R. Patrick

Employees: 60

ARMP Company Website

ARMP Investor Relations

Phone: 13106652928

ARMATA PHARMACEUTICALS INC / ARMP FAQ

What does ARMATA PHARMACEUTICALS INC do?

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 60 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.


What is the current price of ARMP stock?

The current stock price of ARMP is 12.88 USD. The price increased by 10.18% in the last trading session.


What is the dividend status of ARMATA PHARMACEUTICALS INC?

ARMP does not pay a dividend.


What is the ChartMill rating of ARMATA PHARMACEUTICALS INC stock?

ARMP has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What is the analyst forecast for ARMP stock?

8 analysts have analysed ARMP and the average price target is 15.3 USD. This implies a price increase of 18.79% is expected in the next year compared to the current price of 12.88.


What sector and industry does ARMATA PHARMACEUTICALS INC belong to?

ARMATA PHARMACEUTICALS INC (ARMP) operates in the Health Care sector and the Biotechnology industry.


Who owns ARMATA PHARMACEUTICALS INC?

You can find the ownership structure of ARMATA PHARMACEUTICALS INC (ARMP) on the Ownership tab.